Aurinia Pharmaceuticals (Aurinia) is a late-stage clinical biopharmaceutical company (Toronto Stock Exchange (TSX:AUP); NASDAQ (NASDAQ:AUPH) focused on commercializing therapies for rare autoimmune and inflammatory conditions.
Sara Nayeem, M.D. is a Partner at New Enterprise Associates (NEA), a large diversified venture capital firm. Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara (IMRA), Tiburio, and a stealth targeted oncology company.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
Aurinia Appoints Joe Miller as Chief Financial Officer APRIL 27, 2020 VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical [….]